The accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies
dc.contributor.author | Roberts, G | |
dc.contributor.author | Donaghy, PC | |
dc.contributor.author | Lloyd, J | |
dc.contributor.author | Durcan, R | |
dc.contributor.author | Petrides, G | |
dc.contributor.author | Colloby, SJ | |
dc.contributor.author | Lawley, S | |
dc.contributor.author | Ciafone, J | |
dc.contributor.author | Hamilton, CA | |
dc.contributor.author | Firbank, M | |
dc.contributor.author | Allan, L | |
dc.contributor.author | Barnett, N | |
dc.contributor.author | Barker, S | |
dc.contributor.author | Olsen, K | |
dc.contributor.author | Howe, K | |
dc.contributor.author | Ali, T | |
dc.contributor.author | Taylor, J-P | |
dc.contributor.author | O'Brien, J | |
dc.contributor.author | Thomas, AJ | |
dc.date.accessioned | 2020-11-02T16:46:57Z | |
dc.date.issued | 2020-12-23 | |
dc.description.abstract | Background: Dopaminergic imaging is an established biomarker for dementia with Lewy bodies, but its diagnostic accuracy at the mild cognitive impairment stage remains uncertain. Aims: To provide robust prospective evidence of the diagnostic accuracy of dopaminergic imaging at the mild cognitive impairment stage to either support or refute its inclusion as a biomarker for the diagnosis of mild cognitive impairment with Lewy bodies. Methods: We conducted a prospective diagnostic accuracy study of baseline dopaminergic imaging with 123-I-FP-CIT SPECT in 144 patients with mild cognitive impairment (MCI). Images were rated as normal or abnormal by a panel of experts with access to striatal binding ratio results. Follow-up consensus diagnosis based on the presence of core features of Lewy body disease was used as the reference standard. Results: At latest assessment (mean 2 years) 61 patients had probable MCI with Lewy bodies, 26 possible MCI with Lewy bodies and 57 MCI due to Alzheimer’s disease. The sensitivity of baseline FPCIT visual rating for probable MCI with Lewy bodies was 66% (95% CI 52 to 77%), specificity 88% (76 to 95%) and accuracy 76% (68 to 84%), with positive likelihood ratio 5.3. Conclusions: It is over five times as likely for an abnormal scan to be found in probable MCI with Lewy bodies than MCI due to Alzheimer’s disease. Dopaminergic imaging appears to be useful at the mild cognitive impairment stage, in cases where Lewy body disease is suspected clinically. | en_GB |
dc.description.sponsorship | Alzheimer’s Research UK | en_GB |
dc.identifier.citation | Published online 23 December 2020 | en_GB |
dc.identifier.doi | 10.1192/bjp.2020.234 | |
dc.identifier.grantnumber | ARUK-PG2015-13 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/123465 | |
dc.language.iso | en | en_GB |
dc.publisher | Cambridge University Press (CUP) / Royal College of Psychiatrists | en_GB |
dc.rights | © The Authors 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
dc.subject | Mild cognitive impairment | en_GB |
dc.subject | Dopaminergic imaging | en_GB |
dc.subject | diagnostic accuracy | en_GB |
dc.subject | 123-I-FP-CIT | en_GB |
dc.subject | ioflupane | en_GB |
dc.subject | DaTSCAN | en_GB |
dc.subject | visual rating | en_GB |
dc.subject | specific binding ratio | en_GB |
dc.title | The accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2020-11-02T16:46:57Z | |
dc.identifier.issn | 0007-1250 | |
dc.description | This is the final version. Available on open access from Cambridge University Press via the DOI in this record | en_GB |
dc.identifier.eissn | 1472-1465 | |
dc.identifier.journal | British Journal of Psychiatry | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2020-10-27 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2020-10-27 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2020-11-02T16:16:16Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2021-01-15T16:06:11Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Authors 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.